Comments on: Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC)

Comments on: Ipsen Receives Positive CHMP Opinion for Cabometyx® (Cabozantinib) for the Second-line Treatment of Patients with Hepatocellular Carcinoma (HCC) https://www.novumpr.nl/2018/09/21/ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-the-second-line-treatment-of-patients-with-hepatocellular-carcinoma-hcc/?utm_source=rss&utm_medium=rss&utm_campaign=ipsen-receives-positive-chmp-opinion-for-cabometyx-cabozantinib-for-the-second-line-treatment-of-patients-with-hepatocellular-carcinoma-hcc NovumPR press releases Fri, 21 Sep 2018 09:37:45 +0000 hourly 1 https://wordpress.org/?v=6.8.2